BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center For Technology Licensing - ECPv6.11.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Center For Technology Licensing
X-ORIGINAL-URL:https://ctl.cornell.edu
X-WR-CALDESC:Events for Center For Technology Licensing
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260410T120000
DTEND;TZID=America/New_York:20260410T130000
DTSTAMP:20260407T150104
CREATED:20260303T213310Z
LAST-MODIFIED:20260303T213622Z
UID:10000593-1775822400-1775826000@ctl.cornell.edu
SUMMARY:Ignite Innovation Acceleration Spring 2026 Information Session 3
DESCRIPTION:Ignite Innovation Acceleration is a gap funding program offering up to $50\,000 to help Cornell research teams advance disclosed inventions toward commercialization. Funding supports work that moves technologies toward licensing\, startup formation\, or industry partnerships. \nApplications are open from March 2 to April 24\, 2026. \nWho Should Apply?\n\n\nCornell faculty \n\n\nPostdoctoral researchers \n\n\nPhD innovators \n\n\nResearch teams developing technologies with commercial potential \n\n\nJoin our next info session on April 10 at noon. This session will provide an overview of: \n\n\nProgram goals and funding scope \n\n\nApplication process and timeline \n\n\nEligibility and selection criteria \n\n\nHow this program fits into the Ignite: Lab to Market funding series \n\n\nRegister here.
URL:https://ctl.cornell.edu/event/ignite-innovation-acceleration-spring-2026-information-session-3
CATEGORIES:CTL Events,Ignite,Info Sessions
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2022/09/Feature-Image_IgniteIA-700x497-1-e1772573231168.png
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260429T120000
DTEND;TZID=America/New_York:20260429T130000
DTSTAMP:20260407T150104
CREATED:20260315T161851Z
LAST-MODIFIED:20260402T204915Z
UID:10000594-1777464000-1777467600@ctl.cornell.edu
SUMMARY:Lab to Impact: The Rocky Road to Instant Ice Cream
DESCRIPTION:Join us for a discussion on the journey from scientific breakthrough to commercial success in food technology. \nUsing the evolution of instant ice cream as a case study\, this session explores what it takes to move from lab innovation to a product people trust\, adopt\, and buy. \nOur speakers—spanning academia\, entrepreneurship\, and industry—will share firsthand perspectives on navigating regulatory requirements\, scaling production\, and building a viable business around novel food technologies. \nWe’ll cover:\n• Bridging research and commercial viability\n• Navigating food safety regulations\n• Scaling production while maintaining quality\n• Building consumer trust\n• Securing investment and partnerships \nSpeakers: Syed Ruzvi\, professor at Cornell CALS\, and Aris Despo\, seasoned tech entrepreneur. Hosted by Marie Donnelly\, Business Development and Licensing Manager at CTL. \nRegister here. 
URL:https://ctl.cornell.edu/event/lab-to-impact-the-rocky-road-to-instant-ice-cream
CATEGORIES:CTL Events
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2024/09/CTL_CommVenture_icon2-e1770768070564.png
LOCATION:https://ctl.cornell.edu/event/lab-to-impact-the-rocky-road-to-instant-ice-cream
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260506T120000
DTEND;TZID=America/New_York:20260506T130000
DTSTAMP:20260407T150104
CREATED:20260315T162222Z
LAST-MODIFIED:20260407T180804Z
UID:10000595-1778068800-1778072400@ctl.cornell.edu
SUMMARY:Lab to Impact: The Hard Reality of Building a Biotech Startup - A CEO's Perspective
DESCRIPTION:What does it take to build a biotechnology company that advances early academic assets into a therapy used at the bedside\, while overcoming the scientific\, clinical\, and financial hurdles along the way? \nIn this session\, Laurence Blumberg\, MD\, MBA\, a physician and serial biotech entrepreneur\, shares a candid perspective drawn from decades of experience founding biotechnology companies and advancing scientific discoveries into clinical development. As founding CEO of Syntimmune\, he guided the company through early clinical development before its acquisition by Alexion in 2018 for up to $1.2 billion. Earlier\, he co-founded Syntonix Pharmaceuticals\, where his early strategic vision helped shape a protein engineering platform later acquired by Biogen in 2007. That platform ultimately enabled the development of Eloctate and Alprolix\, long-acting therapies for hemophilia A and B that have significantly improved care for patients with bleeding disorders. \nThis conversation examines the operational and strategic realities of building a therapeutics company. Topics will include: \n\nUnderstanding the structure of the biotechnology ecosystem\nDeveloping a rigorous Target Product Profile and market thesis\nDeciding when to build internal capabilities versus leveraging external partners such as CROs and CDMOs\nSecuring the capital and strategic partnerships required to advance therapies through development\n\nResearchers\, physicians\, and aspiring bioentrepreneurs are invited to join this candid conversation. \nHosted by Lynda Inseque\, director of Technology & Venture Initiatives and Engagement at CTL. \nRegister here. 
URL:https://ctl.cornell.edu/event/lab-to-impact-the-hard-reality-of-building-a-biotech-startup-a-ceos-perspective
CATEGORIES:CTL Events
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2024/09/CTL_CommVenture_icon2-e1770768070564.png
LOCATION:https://ctl.cornell.edu/event/lab-to-impact-the-hard-reality-of-building-a-biotech-startup-a-ceos-perspective
END:VEVENT
END:VCALENDAR